Coca-Cola Coliseum to be primary venue for PWHL Toronto in 2024-25 season

MONTREAL – On a night when New York’s top line was missing in action, the bit players grabbed the spotlight and led the Rangers to a commanding 7-2 win over the Montreal Canadiens.

“That’s the kind of team we have,” said Filip Chytil, who led the Rangers with a pair of power-play goals Tuesday. “The guys on the top line had chances but when they don’t score we have three other lines to pick up the slack.”

The Rangers’ dominance was reflected in the amount of time they spent in the Canadiens zone and their 45-23 edge in shots.

“If you’ve watched us practice, you know that’s something we work on all the time,” said Chytil. “When we get the puck, we want to hold on to it.”

The Rangers grabbed a 2-0 lead on goals by Mika Zibanejad at the 56-second mark and Jonny Brodzinski at 2:05, but it was Montreal which pressed the play in the first minute.

“I thought we had a good start but they turned it around on us,” said Montreal coach Martin St. Louis.

Lane Hutson controlled the puck off the opening faceoff and had two early shots, both of which were blocked by New York’s Jacob Trouba.

“That was huge for us,” said Rangers coach Peter Laviolette. “We know (Trouba) can generate offence but he can come up with those big defensive plays.”

Montreal goalie Sam Montembeault exited at 11:05 of the first period after giving up four goals on 10 shots. Zibanejad, Brodzinski, Chytil and Reilly Smith all scored on the Habs’ starter.

His replacement, Cayden Primeau, stopped 33 of 35 shots, giving up goals to Braden Schneider, Kaapo Kakko and Chytil.

Nick Suzuki scored both of the Montreal goals, his first strikes of the season

“It didn’t really feel like a 7-2 game until the end there when you look up at the scoreboard,” Suzuki said. “But we obviously keep digging ourselves these holes, and against a good team like that, our details early on have to be really sharp. And we were definitely a little sleepy coming out and they jumped on us.”

Hutson led the Canadiens in ice time with 24:10 but this wasn’t one of his better games. Smith scored on a breakaway after taking the puck off Hutson’s stick and the rookie was minus-4 for the night.

After Tuesday’s morning practice, the Canadiens announced forward Juraj Slafkovsky will miss at least a week with an upper-body injury. Defenceman Kaiden Guhle missed a second consecutive game with an upper-body injury but the team said it isn’t a long-term ailment.

The injury situation didn’t get any better after Trouba flattened Justin Barron at 7:11 of the third period. Barron didn’t return to the ice but there was no immediate word on his condition.

The Rangers welcomed back defenceman Ryan Lindgren, who made his season debut after missing five games with a jaw injury.

Before the game, 14 players from the Canadiens’ team that won four consecutive Stanley Cups between 1976 and 1979 were introduced at the Bell Centre. Among them were Hockey Hall of Fame members Yvan Cournoyer, Serge Savard, Guy Lapointe, Bob Gainey and Ken Dryden.

This report by The Canadian Press was first published Oct. 22, 2024.

The Canadian Press. All rights reserved.

The Canadian Paediatric Society says doctors should regularly screen children for reading difficulties and dyslexia, calling low literacy a “serious public health concern” that can increase the risk of other problems including anxiety, low self-esteem and behavioural issues, with lifelong consequences.

New guidance issued Wednesday says family doctors, nurses, pediatricians and other medical professionals who care for school-aged kids are in a unique position to help struggling readers access educational and specialty supports, noting that identifying problems early couldhelp kids sooner — when it’s more effective — as well as reveal other possible learning or developmental issues.

The 10 recommendations include regular screening for kids aged four to seven, especially if they belong to groups at higher risk of low literacy, including newcomers to Canada, racialized Canadians and Indigenous Peoples. The society says this can be done in a two-to-three-minute office-based assessment.

Other tips encourage doctors to look for conditions often seen among poor readers such as attention-deficit hyperactivity disorder; to advocate for early literacy training for pediatric and family medicine residents; to liaise with schools on behalf of families seeking help; and to push provincial and territorial education ministries to integrate evidence-based phonics instruction into curriculums, starting in kindergarten.

Dr. Scott McLeod, one of the authors and chair of the society’s mental health and developmental disabilities committee, said a key goal is to catch kids who may be falling through the cracks and to better connect families to resources, including quicker targeted help from schools.

“Collaboration in this area is so key because we need to move away from the silos of: everything educational must exist within the educational portfolio,” McLeod said in an interview from Calgary, where he is a developmental pediatrician at Alberta Children’s Hospital.

“Reading, yes, it’s education, but it’s also health because we know that literacy impacts health. So I think that a statement like this opens the window to say: Yes, parents can come to their health-care provider to get advice, get recommendations, hopefully start a collaboration with school teachers.”

McLeod noted that pediatricians already look for signs of low literacy in young children by way of a commonly used tool known as the Rourke Baby Record, which offers a checklist of key topics, such as nutrition and developmental benchmarks, to cover in a well-child appointment.

But he said questions about reading could be “a standing item” in checkups and he hoped the society’s statement to medical professionals who care for children “enhances their confidence in being a strong advocate for the child” while spurring partnerships with others involved in a child’s life such as teachers and psychologists.

The guidance said pediatricians also play a key role in detecting and monitoring conditions that often coexist with difficulty reading such as attention-deficit hyperactivity disorder, but McLeod noted that getting such specific diagnoses typically involves a referral to a specialist, during which time a child continues to struggle.

He also acknowledged that some schools can be slow to act without a specific diagnosis from a specialist, and even then a child may end up on a wait list for school interventions.

“Evidence-based reading instruction shouldn’t have to wait for some of that access to specialized assessments to occur,” he said.

“My hope is that (by) having an existing statement or document written by the Canadian Paediatric Society … we’re able to skip a few steps or have some of the early interventions present,” he said.

McLeod added that obtaining specific assessments from medical specialists is “definitely beneficial and advantageous” to know where a child is at, “but having that sort of clear, thorough assessment shouldn’t be a barrier to intervention starting.”

McLeod said the society was partly spurred to act by 2022’s “Right to Read Inquiry Report” from the Ontario Human Rights Commission, which made 157 recommendations to address inequities related to reading instruction in that province.

He called the new guidelines “a big reminder” to pediatric providers, family doctors, school teachers and psychologists of the importance of literacy.

“Early identification of reading difficulty can truly change the trajectory of a child’s life.”

This report by The Canadian Press was first published Oct. 23, 2024.

LONDON (AP) — Britain’s drug regulator approved the Alzheimer’s drug Kisunla on Wednesday, but the government won’t be paying for it after an independent watchdog agency said the treatment isn’t worth the cost to taxpayers.

It is the second Alzheimer’s drug to receive such a mixed reception within months. In August, the U.K. regulator authorized Leqembi while the same watchdog agency issued draft guidance recommending against its purchase for the National Health Service.

In a statement on Wednesday, Britain’s Medicines and Healthcare regulatory Agency said Kisunla “showed some evidence of efficacy in slowing (Alzheimer’s) progression” and approved its use to treat people in the early stages of the brain-robbing disease. Kisunla, also known as donanemab, works by removing a sticky protein from the brain believed to cause Alzheimer’s disease.

Meanwhile, the National Institute for Health and Care Excellence, or NICE, said more evidence was needed to prove Kisunla’s worth — the drug’s maker, Eli Lilly, says a year’s worth of treatment is $32,000. The U.S. Food and Drug Administration authorized Kisunla in July. The roll-out of its competitor drug Leqembi has been slowed in the U.S. by spotty insurance coverage, logistical hurdles and financial worries.

NICE said that the cost of administering Kisunla, which requires regular intravenous infusions and rigorous monitoring for potentially severe side effects including brain swelling or bleeding, “means it cannot currently be considered good value for the taxpayer.”

Experts at NICE said they “recognized the importance of new treatment options” for Alzheimer’s and asked Eli Lilly and the National Health Service “to provide additional information to address areas of uncertainty in the evidence.”

Under Britain’s health care system, most people receive free health care paid for by the government, but they could get Kisunla if they were to pay for it privately.

“People living with dementia and their loved ones will undoubtedly be disappointed by the decision not to fund this new treatment,” said Tara Spires-Jones, director of the Centre for Discovery Brain Sciences at the University of Edinburgh. “The good news that new treatments can slow disease even a small amount is helpful,” she said in a statement, adding that new research would ultimately bring safer and more effective treatments.

Fiona Carragher, chief policy and research officer at the Alzheimer’s Society, said the decision by NICE was “disheartening,” but noted there were about 20 Alzheimer’s drugs being tested in advanced studies, predicting that more drugs would be submitted for approval within years.

“In other diseases like cancer, treatments have become more effective, safer and cheaper over time,” she said. “ We hope to see similar progress in dementia.”

___

The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute’s Science and Educational Media Group. The AP is solely responsible for all content.

The Canadian Press. All rights reserved.